Direct-Acting Antiviral Agents and the Path to Interferon Independence

Warren N Schmidt; David R Nelson; Jean–Michel Pawlotsky; Kenneth E Sherman; David L Thomas; Raymond T Chung

doi:10.1016/j.cgh.2013.06.024

Back

Direct-Acting Antiviral Agents and the Path to Interferon Independence

Journal article

Open access

Peer reviewed

Direct-Acting Antiviral Agents and the Path to Interferon Independence

Warren N Schmidt, David R Nelson, Jean–Michel Pawlotsky, Kenneth E Sherman, David L Thomas and Raymond T Chung

Clinical gastroenterology and hepatology, Vol.12(5), pp.728-737

05/2014

DOI: 10.1016/j.cgh.2013.06.024

PMCID: PMC4049632

PMID: 23872239

Files and links (1)

url

https://doi.org/10.1016/j.cgh.2013.06.024View

Published (Version of record) Open Access

Abstract

Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies. Studies of interferon-α–based therapies have helped define treatment parameters, and these treatment strategies have cured a substantial percentage of patients. However, interferon-α must be injected; there are problems with tolerability, adherence, and incomplete response in a large percentage of patients. New drug candidates designed to target the virus or the host have recently been introduced at an unprecedented pace. In phase I–III studies, these agents have exceeded expectations and achieved rates of response previously not thought possible. We are, therefore, entering a new era of therapy for HCV infection and interferon independence.

Non-nucleoside

NS3/4A Protease Inhibitor

Nucleoside/Nucleotide

DAA

Details

Title: Subtitle: Direct-Acting Antiviral Agents and the Path to Interferon Independence
Creators: Warren N Schmidt - Department of Internal Medicine and Research Service, Veterans Affairs Medical Center, Iowa City, Iowa
David R Nelson - University of Florida, Section of Hepatobiliary Disease, Gainesville, Florida
Jean–Michel Pawlotsky - National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Henri Mondor Hospital, University of Paris-Est, Créteil, France
Kenneth E Sherman - University of Cincinnati, College of Medicine, Division of Digestive Diseases, Hepatology Section, Cincinnati, Ohio
David L Thomas - Johns Hopkins Medical Institution, Baltimore, Maryland
Raymond T Chung - GI Division and Liver Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Resource Type: Journal article
Publication Details: Clinical gastroenterology and hepatology, Vol.12(5), pp.728-737
DOI: 10.1016/j.cgh.2013.06.024
PMID: 23872239
PMCID: PMC4049632
NLM abbreviation: Clin Gastroenterol Hepatol
ISSN: 1542-3565
eISSN: 1542-7714
Publisher: Elsevier Inc
Grant note: K24 DK070528 / University of Iowa Doriann Foundation for hepatitis research Anadys Genentech Gilead BMS Boehringer-Ingelheim Abbott Novartis Vertex Merck BX000159 / Veterans Affairs
Language: English
Date published: 05/2014
Academic Unit: Gastroenterology and Hepatology; Internal Medicine
Record Identifier: 9984094642502771

Metrics

23 Record Views

31 Times Cited - Web of Science